India
Shreya Life Sciences launches Oral-Recosulin for diabetics
Hyderabad | Friday, Nov 21 2008 IST
Shreya Life Sciences, India, today announced launch of the world's first recombinant DNA human insulin buccal spray under the brand name of Oral-Recosulin. Ultra Rapid Prandial Glucose Regulator is a buccal insulin spray for the treatment of Type I and Type II diabetes that is based on the technology developed by the company's US collaborator Generex Biotechnology. Through its breakthrough RapidMist technology in insulin delivery, Oral Recosulin provides freedom from limitations of conventional insulin therapy/devices. The new technology delivers insulin through Buccal Mucosa directly to the Vascular System. In a press release here Company Director (Domestic Business) Ram Shelat said Oral-Recosulin was an alternative available for those diabetics, who have an acute injection phobia. ''We feel that Oral-Recosulin is a simple solution for a worldwide problem, as diabetics would prefer buccal delivery of the drug to injections because it offers superior pharmacodynamic profile besides being pain free, he said. Chairman and Managing Director Sujit Kumar Singh said, ''we are committed in bringing world-class diabetes therapy to India and are making major efforts to improve the quality life of diabetics.'' -- (UNI) -- 21MS21.xml
Viewer's Comment |
Comments Not Available |
|
| |
Villagers rue underdevelopment, government apathy ahead of UP polls Political temperatures at its zenith in poll-bound Uttar Pradesh Anderson says England batsmen confident despite \'nerve-wracking\' display in third Test Beni Prasad Verma dubs BJP a \'militant outfit\' Mayawati plays caste card, accuses Centre of scuttling development projects Mamata accuses Left of poor governance in West Bengal 2G scam: Court defers order on Chidambaram till 12:30 p.m. 35 percent of candidates in UP polls tainted
| 
